SCHEMBL1459337

SCHEMBL1459337

Cc1cc(C)cc(CC(=O)N[C@H](Cc2ccccc2)C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
ACE P12821 5/20 0.56
CTSL P07711 1/20 0.56
CTSB P07858 1/20 0.56
CTSS P25774 1/20 0.56
ITGB3 P05106 1/20 0.54
ITGA2B P08514 1/20 0.54
MME P08473 2/20 0.52
CPA1 P15085 1/20 0.52
ACE2 Q9BYF1 1/20 0.52
PSMB8 P28062 1/20 0.52
PSMB5 P28074 1/20 0.52
KMT2A Q03164 1/20 0.52
CNR1 P21554 1/20 0.51
CNR2 P34972 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458913 1.00 TACR1 (0.56) TACR1L3MBTL1ACECTSLCTSB
SCHEMBL1458962 1.00 TACR1 (0.56) TACR1L3MBTL1ACECTSLCTSB
SCHEMBL1458363 0.89 ACE (0.57) TACR1ACEITGB3ITGA2BMME
SCHEMBL1459346 0.88 PSMB8 (0.67) L3MBTL1ACECTSLCTSBCTSS
SCHEMBL1458952 0.88 PSMB8 (0.67) L3MBTL1ACECTSLCTSBCTSS
SCHEMBL4144668 0.88 ITGB3 (0.65) L3MBTL1ACECTSLCTSBCTSS
SCHEMBL10504767 0.88 ITGB3 (0.65) L3MBTL1ACECTSLCTSBCTSS
SCHEMBL4144665 0.88 ITGB3 (0.65) L3MBTL1ACECTSLCTSBCTSS
SCHEMBL1458909 0.87 TACR1 (0.63) TACR1L3MBTL1KMT2A
SCHEMBL1458910 0.87 TACR1 (0.63) TACR1L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822698-B2 Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family UNIVERSITE D'AIX-MARSEILLE (FR) 2014-09-02 US disclosed
US-20130085143-A1 AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY UNIVERSITE D'AIX-MARSEILLE (FR) 2013-04-04 US disclosed
EP-2483280-A1 NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY Université d'Aix-Marseille (FR) 2012-08-08 EP disclosed
EP-2305688-A1 Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors Université de la Méditerranée - Aix-Marseille II (FR) 2011-04-06 EP disclosed
WO-2011036303-A1 NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) 2011-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085143-A1 AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY MET, HGFAC, HRAS TACR1 4287/4885L3MBTL1 705/4885ACE 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.